EGFR and non-small cell lung carcinoma: Previous evidence has demonstrated that, compared with 1G TKIs, the 2G TKI afatinib has a more favorable effect on PFS in patients with NSCLC harboring uncommon EGFR mutations (afatinib vs. gefitinib vs. erlotinib: 10.5 months vs. 3.0 months vs. 0.9 months, p = 0.013) [29].